Evaluation of the Tolerance of Anti-MRSA Betalactamines (Ceftaroline / Ceftobiprole) in the Management of BJI / PJI: a Retrospective Study in a Reference Center
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Evaluation of use of ceftaroline and ceftobiprole : patients
研究概览
简要总结
Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. Vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option.
Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. As some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients having had a PJI or BJI treated whith ceftaroline and/or ceftobiprole
排除标准
- 未提供
结局指标
主要结局
Evaluation of use of ceftaroline and ceftobiprole : patients
时间窗: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
type of patients: age, CMI
Evaluation of use of ceftaroline : PJI/BJI
时间窗: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
description of the PJI/BJI treated by ceftaroline : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection
Evaluation of use of ceftobiprole: dosage
时间窗: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
dosage, duration
Evaluation of use of ceftaroline: dosage
时间窗: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
dosage,duration
rate of failure under ceftobiprole
时间窗: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
Evaluation of use of ceftobiprole: PJI/BJI
时间窗: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
description of the PJI/BJI treated by ceftobiprole : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection
rate of failure under ceftaroline
时间窗: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
次要结局
- Treatment-related adverse events(2 months)